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Title: Autoantibodies against voltage-gated potassium channel (VGKC) and glutamic acid 
decarboxylase (GAD) in psychosis: A systematic review, meta-analysis and case series 
Abstract 
Antibodies to the voltage-gated potassium channel (VGKC) complex and glutamic acid 
decarboxylase (GAD) have been reported in some cases of psychosis.  We conducted the first 
systematic review and meta-analysis to investigate their prevalence in people with psychosis and 
report a case series of VGKC-complex antibodies in refractory psychosis. Only five studies 
presenting prevalence rates of VGKC seropositivity in psychosis were identified, in addition to our 
case series, with an overall prevalence of 1.5% (25/1720) compared to 0.7% in healthy controls 
(12/1753).   
Meta-analysis established the pooled prevalence of GAD65 autoantibodies was 5.8%(95%CI:2.0-
15.6%;I2=91%;9 studies) in psychotic disorders,with a prevalence of 4.6%(95%CI:1.2-15.9%;9 
studies;I2=89%%) and 6.2% (95%CI:1.2-27.0%;2 studies;I2=69%) in schizophrenia and bipolar 
disorder respectively.  People with psychosis were more likely to have GAD65 antibodies than 
controls (OR 2.24;95%CI:1.28- 3.92%;p=0.005;8 studies;I2=0%).Among 21 participants with 
treatment-resistant psychosis, none had VGKC antibodies. 
The prevalence of VGKC antibodies is low in psychosis.  Our preliminary meta-analysis suggests 
GAD autoantibodies are more common in people with psychosis than in controls, although few 
studies accounted for the possibility of co-existing type 1 diabetes mellitus and the clinical 
significance of reported GAD titres remains unclear. The paucity of studies reporting thresholds for 
  
defining GAD abnormality, and rates of comorbid type 1 DM,preclude interpretations regarding the 
influence of GAD antibodies on the development of psychotic disorders;and may have led to an 
overestimate of the prevalence of GAD. Our case series fails to support the hypothesis that VGKC 
antibodies are linked to treatment resistance in psychosis, but the literature to date is remarkably 
sparse. 
Keywords: Antibodies; Encephalitis; Glutamic acid decarboxylase; Schizophrenia; Voltage-gated 
potassium channel complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Title: VGKC and GAD antibodies in psychosis; A systematic review, meta-analysis and case series. 
 
1. Introduction 
Over recent years interest in a possible autoimmune aetiology of psychosis has grown. (1, 2)  It has 
long been known that people with schizophrenia and their families have a higher risk of 
autoimmune disease than the general population. (3-6) Latterly there has been has been interest in 
the sub-group of people with psychosis who have serum antibodies to neuronal antigens. (1, 7, 8) 
Most current interest focuses on antibodies to the N-Methyl-D-Aspartate receptor (NMDA-R); 
Voltage Gated Potassium Channel (VGKC) complexes and Glutamic Acid decarboxylase 
(GAD).(9-12) A previous meta-analysis identified NMDA-R positivity in 7.98% (n=115/1441) of 
schizophrenia spectrum psychosis.(8) Given this previous review of NMDA-R antibodies, we will 
not discuss these further in our study. Psychosis is a common feature of the encephalitis syndromes 
that are classically associated with these antibodies – often as an early feature before the 
development of other features of encephalitis, such as seizures, movement disorders, autonomic 
instability and impaired consciousness.(13, 14)  The importance of these antibodies is clear when 
psychosis presents in the context of encephalitis, but the challenge in psychiatry is to determine 
their relevance in clinically uncomplicated psychosis.   
VGKC-complex antibodies 
VGKC antibody-mediated limbic encephalitis was first described in 2001.(15)  Most VGKC-
complex antibodies are directed against neuronal cell surface antigens, where they bind to leucine-
rich glioma inactivated-1 (LGI-1) or contactin-associated protein-2 (CASPR-2) which are cell 
  
surface proteins that form part of the VGKC-complex.(16)  The targets of other VGKC-complex 
antibodies are unclear. By 2004, Vincent et al. reported a retrospective case series of 10 patients 
with VGKC antibody-mediated limbic encephalitis, several of whom had experienced psychiatric 
symptoms such as hallucinations (n=3), depression (n=1), anxiety and delusions (n=1). (17)  A 
later retrospective case series of 152 US patients who tested positive for serum VGKC antibodies, 
reported neuropsychiatric symptoms in 44%, in particular anxiety and depression, with two patients 
initially given psychiatric diagnoses.(18) 
GAD antibodies 
Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme for the generation of gamma 
amino-butyric acid (GABA), the main inhibitory central nervous system neurotransmitter.(19) 
There are two subtypes of GAD. GAD65 is present in both pancreatic islet cells and neuronal tissue, 
while GAD67 is present mainly in neuronal tissue.(20) 
GAD autoantibodies are directed against intracellular synaptic antigens, and are found in several 
neurological conditions such as Stiff person syndrome (SPS), limbic encephalitis and epilepsy. (21) 
It is unclear whether the presence of GAD65 in these disorders is pathogenic or an epiphenomenon 
of another immune dysfunction.  
GAD65 antibodies are also a marker for Type 1 diabetes and latent autoimmune diabetes of 
adulthood (LADA). (22, 23) Patients with schizophrenia have an increased risk of type 1 
diabetes.(3)  
Aims of the current paper 
There is no previous systematic review investigating the prevalence of VGKC seropositivity in 
psychosis. A systematic review of the prevalence of a variety of other antibodies in schizophrenia 
identified four studies assessing for GAD antibodies. (11) 
  
Given the aforementioned, we conducted a systematic review and meta-analysis to determine the 
prevalence of VGKC-complex and GAD antibodies in psychosis. The coprimary outcomes were the 
prevalence of study-defined VGKC and GAD positivity in psychosis. Secondary outcomes included 
the comparison of the coprimary outcomes in diagnostic subgroups (e.g. schizophrenia; bipolar 
disorder) with healthy controls. In addition we aimed to describe the clinical characteristics of 
patients with VGKC-complex and GAD65 antibody-positive psychotic illness.  Within the second 
stage of this paper, we conducted a retrospective case series to investigate VGKC-complex 
antibodies in patients with refractory psychosis.   
  
 
2. Methods 
This systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) standard. (24) 
2.1 Inclusion and exclusion criteria 
Included in this systematic review were studies which included subjects 1) with a diagnosis of, or 
who were being treated for, a psychotic illness, 2) where serum or cerebrospinal fluid (CSF) was 
analysed for the presence of VGKC or GAD antibodies, 3) comparative (contained a healthy control 
group) or non-comparative (without a control group) studies and prevalence or observational studies 
4) studies in peer reviewed journals, 5) written in English and 6) published before June 2016.  
The exclusion criteria were 1) studies in which subjects were screened for antibodies as part of a 
medical work-up without an actual or suspected psychiatric diagnosis; 2) studies where individuals 
were diagnosed with an organic psychosis from the outset; 3) studies which were not reported in 
English. 
 
2.2 Information sources and searches 
Two independent reviewers (RG, JL) performed an electronic search using Medline, PsychInfo, 
Pubmed, Scopus and Google Scholar from database inception to June 2016. The following basic 
search terms were used, both alone and in combinations: 'psychosis' 'psychotic'(and truncated terms 
psychos*, psychot*), 'schizophrenia' 'schizoaffective' and 'bipolar' were combined with 'gad' 
'glutamic acid decarboxylase' 'glutamate decarboxylase' 'diabetes', 'VGKC' 'voltage-gated potassium 
channels' 'CASPR', and 'LGI1' and 'antibodies', 'antibody' and 'antibod*'. 
  
'VGKC' alone was also searched to identify all records in Pubmed. The abstracts of the 2012, 2014, 
and 2016 SIRS (Schizophrenia International Research Society) and the 2009, 2011, 2013 and 2015 
ICOSR (International Congress on Schizophrenia Research) conferences were searched for 
abstracts containing 'antibod*' to identify any unpublished works. The bibliographies of included 
studies and literature reviews were also hand searched. The titles of all articles retrieved were 
screened, and the abstracts of those considered potentially relevant were read. All articles 
considered relevant at this initial screening were retrieved and taken to full reading. A hand search 
of the references of retrieved articles was conducted to identify additional studies. When required, 
we contacted the primary/corresponding authors of potential studies to (a) confirm eligibility, and 
(b) acquire the variables of interest if they were not available in the publication.  
2.3 Study selection and exclusion 
All applicable abstracts were obtained, and examined by two reviewers (RG & JL). The two authors 
applied the eligibility criteria and a list of full text articles was developed through consensus.  
2.4 Data extraction  
Articles were critically reviewed by two authors (RG and JL) and the following information 
extracted where available: clinical characteristics and outcomes; size of the cohort; diagnoses and 
any control groups; antibodies tested;  threshold for antibody positivity; numbers and proportions of 
patients with antibody positivity. 
2.5 Meta-analysis 
If data were sufficient, we anticipated conducting a random effects -analysis with Comprehensive 
Meta-Analysis software (CMA, Version 3). First, we calculated the prevalence of GAD65 antibody 
positivity in each diagnostic subgroup (all psychotic disorders, schizophrenia, bipolar disorder and 
controls) together with 95% confidence intervals (CI).  We then compared the prevalence of 
GAD65 antibodies in each SMI cohort separately with the controls to determine the odds ratio (OR) 
  
and 95% CI.  Heterogeneity was assessed with the Cochran Q and I2 statistics for each analysis. 
(25)  Publication bias was assessed with a visual inspection of funnel plots and with the Begg-
Mazumdar Kendall's tau (26)and Egger bias test. (27) 
2.6 Case series 
A retrospective case series was obtained from a cohort of inpatients to a specialist service with 
treatment resistant psychotic disorders (International Classification of Diseases (ICD)-10 (F20-F29 
and F30-F33)). 
The clinical notes of 203 consecutive admissions with treatment resistant psychosis between 2009 
and 2015 were reviewed. Routine socio-demographic and clinical data (gender, age, diagnosis, and 
duration of illness) were collected along with VGKC-complex antibody status where available. 
Serological analyses were performed by Professor Angela Vincent at the Department of Clinical 
Neurology, John Radcliffe Hospital, University of Oxford. Serum VGKC-complex antibodies were 
tested using a radio-immunoprecipitation assay.(28) 
2.7 Ethics 
Study approval was granted by the Psychosis Clinical Academic Group Audit committee at South 
London and Maudsley NHS Foundation Trust, London UK. All clinical information was 
anonymised. . 
3. Results 
3.1 Systematic review 
The results of the selection process are summarised in a flow diagram (Figure 1 ).  
Insert figure 1 here 
3.2 VGKC Studies 
  
The results of the VGKC studies are summarised in Table 1. 
Insert table 1 here 
The literature search revealed five studies reporting on VGKC positivity in psychotic disorders. (10, 
29-32)  Two of the studies measured VGKC antibodies using a radioprecipitation assay, (10, 30) 
while three used an immunofluorescence assay.  (29, 31, 32) One of the studies assessed serum and 
cerebrospinal fluid (CSF) for VGKC positivity.(32)  Only one of the studies defined a cut off for 
VGKC positivity with a VGKC level of > 100 pM established as consistent with positivity.(30) 
3.2 Case series results  
VGKC in treatment refractory psychosis  
Between August 2009 and February 2015, 203 patients with diagnoses of treatment resistant 
psychosis were referred to our specialist inpatient service. Twenty-one patients (12 males) based on 
clinical suspicion, were tested for VGKC-complex antibodies.  The mean age was 38 years 
(SD=17) (range 19 –78 years). Diagnoses were: schizophrenia (n= 14), schizoaffective disorder 
(n=5), psychotic depression (n=2).  The mean duration of illness was 12 years (SD=10) (range=3-33 
years).  All patients tested negative for VGKC-complex antibodies. 
The remaining five studies, (10, 29-32) and our case series, described 1720 patients (1574 
schizophrenia patients, 46 first episode psychosis (FEP), 50 bipolar affective disorder,  and 50 
patients with unstated chronic psychotic disorders) and 1753 controls.  
3.3 VGKC prevalence studies 
The overall prevalence of VGKC-complex antibodies in cases was 1.5% (25/1720), with 0.7% 
(12/1753) in controls. (30, 31)  One of the VGKC-complex antibody-positive patients had a 
diagnosis of FEP, but presented with no distinguishing clinical features from other patients within 
the service.   
 
  
3.4 GAD65 antibody studies 
Table 2 presents the results of the GAD65 studies.  The literature search revealed nine studies 
satisfying eligibility criteria. Eight of these were case control studies (20, 30, 31, 33-37) and one 
was an observational study (with general population rates of GAD65 positivity used for comparison 
in Cohen et al 2005).(38)  All of the included studies assessed serum for GAD antibody positivity. 
Insert table 2 here 
3.5 GAD65 seropositivity in case control and observational studies 
The included studies involved 2019 psychosis patients and 2116 healthy controls. 57 patients were 
positive for GAD65 antibodies, giving a prevalence of 2.8% (57/2019).  Eleven controls (20/2116; 
0.95%) were positive for GAD65 antibodies. Rates of co-morbidity with type 1 diabetes mellitus 
were not given in any of the studies. A definition of GAD positivity defined in units of GAD anti-
bodies was used in only three of the case control studies (GAD positivity defined as GAD65 anti-
bodies >1.05 (20, 33) and positive with GAD levels > 10 U/mL). Two other studies established cut 
off values for GAD positivity at specified percentile of the control groups (97th  percentile (35)and 
98th percentile of the healthy control group GAD level (20)). Of note, only serum titles higher than 
1000 U/ml are generally considered related to neurological pathologies; none of the patients report-
ed in these studies reached that threshold. 
3.6 Diagnostic subgroupings 
The only study in FEP patients reported a GAD65 antibody prevalence rate of 18.75%. These 
patients had no distinguishing features from other FEP patients within the service.  
3.7 Case-control studies 
One study found statistically significant differences in prevalence rates of GAD65 between cases 
and controls. Padmos, Bekris et al. 2004 found that 11.3% of the bipolar disorder group had 
  
positivity for serum antibodies to GAD65 compared with only 2.6% of the healthy control group ( 
p=0.002).(35)   Patients with GAD65 positivity had more active forms of the illness (either 
mania/hypomania or depression) compared with the GAD65 negative patients. GAD65 levels were 
not found to significantly correlate with duration of illness or treatment, symptom severity or rapid 
cycling.  Seven case-control studies did not find statistically significant differences in GAD65 
positivity between cases and controls. (20, 30, 31, 33, 34, 36, 37) 
Yarlagadda, Helvink et al. 2008 found that patients with chronic psychosis and Tardive 
dyskinesia(TD) had significantly higher GAD65 antibody levels compared to chronic psychosis 
patients without TD (p=0.044), with 38.5% of the TD group (5/13) being positive for GAD 65 
antibodies, and no antibodies found in patients without TD (0/7).(34) 
Seven of the case-control studies assessed antibody levels in patient and control groups and two 
found statistically significant differences. Padmos, Bekris et al. 2004 identified a mean GAD65A 
index that was significantly higher in bipolar patients compared with control subjects (p=0.038). In 
the same study there was no significant difference in the mean GAD65 index between 
schizophrenia patients and controls. (35) Yarlagadda, Helvink et al. 2008 found that patients with 
chronic psychosis and Tardive dyskinesia (TD) had significantly higher antibody levels compared 
to chronic psychosis patients without TD (p=0.044), with 38.5% of the TD group (5/13) being 
positive for GAD 65 antibodies, and no antibodies found in patients without TD (0/7).(34) 
3.8 GAD 65 and GAD 67 
Three studies tested for both GAD65 and 67 antibody positivity in patient and control groups, (20, 
31, 35) with significantly increased rates of GAD65, but not GAD67 found in bipolar disorder cases 
in two of the studies. (20, 35) 
4. Meta-analysis results 
There was insufficient data to pool the prevalence of VGKC-complex antibodies. 
  
4.1 GAD65 antibodies 
It was possible to pool data from 9 studies to establish that the pooled prevalence of GAD65 
antibodies among people with psychosis was 5.8% (95% CI 2.0 to 15.6%, I2=91%%, 9 studies) 
with no evidence of publication bias (Begg=-0.14, p=0.6; Egger=-0.43, p=0.84) (Figure 2); the 
prevalence of GAD65antibodies was 4.6% (95% CI 1.2 to 15.9%, 9 studies, I2=89%%; Begg =0.00, 
p=1.0; Egger=1.50, p=0.54) and 6.2% (95% CI 1.2 to 27.0%, 2 studies, I2=69%, ) in schizophrenia 
and bipolar disorder participants respectively.  The prevalence of GAD65 antibodies was 2.7% 
(95% CI 1.0 to 7.0%, Studies=8, I2=73%) among healthy controls. 
Insert figure 2 here 
4.2 Risk of GAD65 antibodies in SMI versus controls 
A comparative meta-analysis established that people with psychosis were more than two times more 
likely to have GAD65 antibodies (OR 2.24 95% CI 1.28 to 2.92%, p= 0.005, 8 studies, I2=0%) than 
controls (Figure 3).  No significant difference was observed in schizophrenia participants versus 
controls (OR 1.49, 95% CI 0.76 to 2.92%, p=0.24, 6 studies, I2=0%).  An increased odds was 
observed in bipolar disorder participants versus controls but caution should be noted as only two 
studies were pooled in the analysis (OR 4.41,  95% CI 1.85 to 10.5, p<0.001, I2=0%).  
Insert figure 3 here 
5. Discussion 
To our knowledge, this is the first systematic, quantitative review of studies on VGKC and GAD 
antibodies in schizophrenia and psychotic spectrum disorders. There are several findings of note. 
We have carried out the largest review of GAD antibodies in psychosis.  Our meta-analysis 
establishes that the prevalence of GAD antibodies among people with psychosis was 5.8% (95% CI 
2.0 to 15.6%), whilst 4.6% (95% CI 1.2 to 15.9%), and 6.2% (95% CI 1.2 to 27.0%) of people with 
schizophrenia and bipolar disorder participants respectively tested positive. Moreover, our 
  
comparative meta-analysis suggests that people with psychosis are at a more than two fold risk of 
having GAD auto antibodies compared to the general population (OR 2.24 95% CI 1.28 to 2.92%, 
p= 0.005). Whilst we generally found low or moderate levels of heterogeneity and no publication 
bias, the sample sizes are relatively small and some methodological differences exist.   
We identified a pooled prevalence rate of 5.8% for GAD65 in psychotic disorders, with a rate of 
2.7% in controls. The case-control studies of GAD65 in psychotic disorders were marked by 
methodological heterogeneity which makes the interpretation of results difficult. Except for Dahm 
et al 2014 and Padmos et al.,2004, studies had small sample sizes, with contrasting methodologies 
used to measure and detect GAD antibodies.  Three studies (30, 33, 34) used the ELISA (Enzyme-
linked immunosorbent assay) method, with GAD levels calculated using absorbance values, rather 
than by antibody titers as in the other of the Yarlagadda group studies.(20) The other studies used 
radioimmunoassays to measure GAD antibodies. 
It is possible that GAD65 antibodies may directly affect the brain. Abnormalities in GABA have 
been implicated in schizophrenia(39, 40) and GAD is the major rate-limiting enzyme in GABA 
production. (41)   
One significant limitation in the available data is the lack of information on co-morbid type 1 
diabetes mellitus, which may have explained some of the findings. Nevertheless, the excess of type 
1 diabetes mellitus in schizophrenia is of a smaller magnitude (3.1%) (4) than the excess of GAD65 
antibodies reported here, and type 1 diabetes mellitus is unlikely to account for all of these findings. 
Further, the paucity of studies defining the threshold for abnormal GAD levels limits interpretation 
of the influence of GAD antibodies on the development of psychotic disorders, particularly since 
GAD antibodies levels of > 1000IU/L are considered to be indicative of a need for immunotherapy 
in neurological disorders. (42) 
We found a low prevalence of VGKC positivity in psychotic disorders, in the context of a paucity 
of prevalence studies. The available data (5 studies) identified 25 patients with VGKC 
  
antibodies.(31, 32, 43) This low prevalence is consistent with the findings in our case series in 
treatment-resistant psychosis where no VGKC antibody-positive patients were identified.  
Contrary to expectations, there was a low prevalence of VGKC positivity, which may be reflective 
of the currently attainable sample size due to a low number of studies. Only two studies have 
assessed VGKC positivity in cases and controls,(30, 31) thus limiting our ability to draw firm 
conclusions, though the majority of cases sampled were drawn from these two studies. In extracting 
data in relation to VGKC-complex antibodies, we compiled an overall prevalence rate, including 
studies assessing for antibodies against any component of the VGKC complex, including LGI1 and 
CASPR antibodies. This method of data extraction may have led to an underestimation of those 
antibodies which are more closely related to encephalitis, namely LGI1 and CASPR.  Further, given 
that VGKC-complex antibody positivity tends to occur in the acute encephalitic stage, the lack of 
data on the stage of illness at which cases were tested for VGKC-complex antibodies is a limitation.  
Thus, we cannot exclude the possibility that the prevalence of VGKC complex antibody positivity 
would be higher in more acute stages of illness, and that negative results in later stages, or more 
chronic stages dose not outrule an autoimmune aetiology. 
 
5.1 Clinical characteristics of VGKC positive cases 
There were no prototypical clinical characteristics reported for these VGCK positive patients 
identified in our review. In Endres et al., 2015, two of the cases presented with neurological 
features, one with fluctuating levels of consciousness , and another with seizures, aphasia and 
stupor.(32) One patient was unfortunately lost to follow-up, although the lack of distinguishing 
factors makes that case clinically important.(43) 
When VGKC antibodies are found in patients with limbic encephalitis with an initial presentation of 
psychotic illness, these cases do not indicate a characteristic phenotypic presentation of VGKC 
antibody-related limbic encephalitis, although neurological signs and seizures should raise 
  
suspicion of this.  Data from case reports of VGKC-complex limbic encephalitis with an initial 
presentation of psychosis (n=5), indicates a broad clinical heterogeneity, including seizure-like 
episodes (n=4), disordered speech (n=3), delusions (n=3), behaviour change (n=2), aggression 
(n=2), depressive symptoms (n=2), auditory and visual hallucinations (n=2) self-harm (n=1) and 
mutism (n=1), and hyponatraemia in three cases.(44-48) 
More studies with larger cohorts are needed in order to give a more robust estimate of the 
prevalence of VGKC antibody positivity in psychosis. This may identify sub groups of patients with 
higher rates of VGKC antibodies, and determine when VGKC antibody testing is indicated. 
 
5.2 Clinical implications of GAD positivity 
This review identified one case report of limbic encephalitis presenting with psychosis in the 
presence of GAD autoantibodies.(49) A female patient was diagnosed with treatment resistant 
schizophrenia aged 17. Subtle abnormal features, such as intermittent semirhythmic diffuse theta 
slowing on EEG monitoring, without epileptiform abnormalities, and episodes of impaired 
responsiveness were not associated with EEG changes, prompted a frontal lobe biopsy that showed 
immunological activity. Serum GAD65 antibody levels were 112 IU/ml (normal range 0-5). 
Treatment with immunosuppressive therapies resulted in some improvement, but not the excellent 
recovery seen in many of the VGKC-complex antibody cases. It is possible that the pathogenesis in 
this case was not GAD autoantibody-mediated and reflected a co-morbid condition. Furthermore, 
the symptom profile in this case was more characteristic of schizophrenia, with no seizure activity, 
neurological signs or hyponatraemia identified.  
5.3 Implications for future research 
Further studies are needed to determine whether GAD65 antibodies are related to the pathogenesis 
of psychotic disorders, and if so with which particular clinical features. Future studies should also 
  
control for potential confounding factors such as age, ethnicity, BMI, antipsychotic medication use, 
stage of illness, and importantly a diagnosis of type 1 diabetes mellitus.  
It is possible that autoimmune-mediated brain changes may occur early in life, with antibody levels 
becoming reduced or undetectable following a long duration of psychosis.  
5.4 Case series of VGKC-complex antibody positivity in TRS 
Our case series found a zero prevalence rate for VGKC antibodies in patients with refractory 
psychosis. The case series was small, with a low frequency of testing. However, the clinicians who 
selected those tested had an interest in autoimmune causes of psychosis, which is likely to have 
introduced an over-estimate rather than an underestimate. It is possible that antibody titres could be 
affected by treatment, as antipsychotic medication can have immunomodulatory effects,(50) and we 
are unable to exclude the possibility that patients are more likely to  test positive for auto-antibodies 
early in the course of their illness or when drug-naive.   Based on this case series, routine testing for 
VGKC antibodies cannot be recommended in refractory psychosis.  
 
 
 
6. Conclusions  
The potential for VGKC and GAD antibodies to cause psychosis is a fairly novel proposal, and 
relatively few studies exist. This review has identified 5 studies on VGKC antibodies in psychosis 
and, including our case series, the prevalence stands at 1.5% ((25/1720). There remain unsolved 
issues and more studies are needed on larger patient cohorts to give a more accurate picture of 
prevalence and the role(s) of these antibodies.  
  
This review identified an overall pooled prevalence rate of 5.8% for GAD65 antibody-positivity in 
psychosis. More studies are needed to gain a more accurate picture of GAD65 antibody prevalence 
in psychosis and to determine whether these antibodies are clinically relevant to the disease process.  
7. Key learning points 
• The first meta-analysis on the relationship of VGKC and GAD antibodies and psychotic 
disorders. 
• There are few studies on VGKC antibody positivity in psychosis, but the available evidence 
indicates a low prevalence (1.5%).  
• Our results do not support the hypothesis that a significant subpopulation of those with 
psychotic disorders are patients with misdiagnosed VGKC-antibody positive autoimmune 
limbic encephalitis. 
• The raw, unadjusted prevalence rates of GAD positivity were 2.8% in psychosis and 0.95% 
in controls. Meta-analysis identified a pooled prevalence for GAD antibodies of 5.8% in 
psychosis compared to 2.7% in healthy controls.  
• More patients were identified as having GAD antibodies, but there are still few studies 
overall and the clinical significance of the titres reported is unclear. A paucity of studies 
reporting on concurrent type 1 diabetes mellitus, indicates that the identified prevalence rate 
of GAD antibodies may be somewhat accounted for by concurrent type 1 DM. 
• Our review demonstrates that patients with psychosis have an increased likelihood of GAD 
antibody positivity- the extent to which this finding contributes to the aetiology of psychotic 
disorders remains uncertain.  
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Figure legends 
Figure 1. Flow diagram of selected article 
Figure 2: Proportion meta-analysis plot (random effects) of GAD65 antibodies in psychotic 
disorders 
Figure 3. Comparison of GAD65 antibodies across 8 studies among people with  psychotic 
disorder and controls  
 
